Sangamo BioSciences Inc


Stock Update (NASDAQ:SGMO): Sangamo Biosciences, Inc. Names New Chief Medical Officer and Chief Business Officer

Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today key leadership appointments to strengthen the company’s clinical and commercial capabilities.

Stock Update (NASDAQ:SGMO): Sangamo Biosciences, Inc.’s Genome Editing Program for Hemoglobinopathies to Transfer to Biogen’s Spin-Off Bioverativ

Sangamo Biosciences, Inc. (NASDAQ:SGMO) announced that its collaborative zinc finger nuclease (ZFN)-mediated genome editing program for hemoglobinopathies will transfer to Bioverativ.

Stock Update (NASDAQ:SGMO): Sangamo Biosciences, Inc. Reports Third Quarter 2016 Financial Results

Sangamo Biosciences, Inc. (NASDAQ:SGMO) reported its third quarter 2016 financial results and provided an update on recent events and development timelines for its therapeutic …

Company Update (NASDAQ:SGMO): Sangamo Biosciences, Inc. Receives Orphan Drug Designation From The FDA For SB-FIX

Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, announced today that the U.

Company Update (NASDAQ:SGMO): Sangamo Biosciences, Inc. Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II

Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, announced that the U.

Company Update (NASDAQ:SGMO): Sangamo Biosciences, Inc. Announces Retirement Of Edward Lanphier As President And CEO

Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, today announced the company has appointed Alexander ‘Sandy’ Macrae, M.

Stock Update (NASDAQ:SGMO): Sangamo Biosciences, Inc. Presents Recent Developments From Research And ZFP Therapeutic® Programs At Annual Meeting of the ASGCT

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, presented new preclinical data from the Company’s proprietary In Vivo Protein Replacement Platform™ …

Healthcare Analysts Weigh In on Exelixis, Inc. (EXEL) and Sangamo Biosciences, Inc. (SGMO) Following Investor Meeting and Quarterly Update

The biotech sector has had a really cruel start to the year. The Nasdaq Biotechnology Index (IBB) is down 26% so far in …

Company Update (NASDAQ:SGMO): Sangamo Biosciences, Inc. Reports Fourth Quarter And Full Year 2015 Financial Results

Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, today reported its fourth quarter and full year 2015 financial results and accomplishments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts